ARS Pharmaceuticals nasal spray neffy for allergic reactions gets FDA review
seekingalpha.com
business
2022-10-21 12:15:40

Grandbrothers Silverback Therapeutics (NASDAQ:SBTX) said the U.S. Food and Drug Administration (FDA) accepted for review ARS Pharmaceuticals' application seeking approval of nasal spray neffy as emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children â‰¥30 kg (66 lbs). If approved, neffy (epinephrine nasal spray) would be the first non-injectable therapy available to patients with allergic reactions (type I) including anaphylaxis, the company said in press release on Friday.
